Investigation of Vital Organ Specific Biomarkers Using Cell-Based Assays after Treatment with the Biofield Energy Treated Test Formulation

, , , , , ,

Cell & Cellular Life Sciences Journal, 4(2) (2019) .


Abstract

The present study aimed to determine the impact of the Biofield Energy Treated test formulation and different cell line mediums on vital organs function. Specific cell based assays were performed based on the vital organs function (bones, heart, liver, lungs, and brain). The test item (TI) and cell line media was divided into two parts; one was untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, James Jeffrey Peoples, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell lines. Cytoprotective action of the test formulation showed a significant restoration of cell viability by 48.3% (at 25.5 µg/mL), 9.3% (at 1 µg/mL), and 64.1% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 48.3% (at 25.5 µg/mL), 9.3% (at 1 µg/mL), and 64.1% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cytoprotective activity in human hepatoma cells (HepG2) showed improved cell viability by 65.4% (at 1 µg/mL), 63.8% (at 1 µg/mL), and 39.4% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinomic human alveolar basal epithelial cells (A549) showed improved cell viability by 28.4% (at 10 µg/mL), 101.7% (at 25.5 µg/mL), and 181.7% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 88.1% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 433.3% and 136.1% at 0.1 and 10 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 87.8% at 1 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 40.1% at 10 µg/mL, and improved cellular protection by 70.1% at 1 µg/mL in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.6% (at 10 µg/mL), 19% (at 10 µg/mL), and 61.2% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 102.3% (at 1 µg/mL), 10.3% (at 25.5 µg/mL), and 38.4% (at 10 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 23.7% (at 0.1 µg/mL), 36.8% (at 25 µg/mL), and 51.9% (at 25 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 471% (at 10 µg/mL), 318.9% (at 10 µg/mL), and 326.2% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.



Add your rating and review

If all scientific publications that you have read were ranked according to their scientific quality and importance from 0% (worst) to 100% (best), where would you place this publication? Please rate by selecting a range.


0% - 100%

This publication ranks between % and % of publications that I have read in terms of scientific quality and importance.


Keep my rating and review anonymous
Show publicly that I gave the rating and I wrote the review



Notice: Undefined index: publicationsCaching in /www/html/epistemio/application/controllers/PublicationController.php on line 2240